Lesley Bester, global business development officer for infectious diseases at Roche Holdings and global spokesperson, Anja von Treskow, answered a speed round of eight questions during the BIO-Europe Spring partnering conference, held in Stockholm, Sweden, about how the big pharma incorporates external innovation into its business model and methods the company has for future-proofing its pipeline.
Lesley Bester, global business development officer for infectious diseases at Roche Holdings and global spokesperson, Anja von Treskow, answered a speed round of eight questions during the BIO-Europe Spring partnering conference, held in Stockholm, Sweden, about how the big pharma incorporates external innovation into its business model and methods the company has for future-proofing its pipeline.
1. What recent developments in the infectious disease field at Roche would you highlight?
In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.
The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.
PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.
Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.
The Belgian drugmaker is boosting its biologics capacity over the pond.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
